The results from phase I pilot studies demonstrated that TCV treatment was safe and well tolerated160–165 (Table 5) and depleted MBP-reactive T cells after only 2 administrations.160 Interestingly, a correlation between MBP-reactive T cell depletion and a 40% reduction in the relapse rate was found in RRMS patients. The gene discussed is MBP; the disease is relapsing-remitting multiple sclerosis.